Table 3 Biomedical activity and application of glycerophospholipids
Subclass | Name | Activity | Medical application | Ref. |
---|---|---|---|---|
PC | PC | Lipolysis in human fat tissue | Cosmetic procedure | Thomas |
Lipolysis in malar, jawline, submental areas and upper arm | Cosmetic procedure | Thomas |
||
Promote adipocyte-specific lipolysis and apoptosis through TNF-α or IL-1β signaling | Adipocyte lipolysis and apoptosis | Jung |
||
Reduce gastric bleeding, prevent GI permeability disturbance due to LPS | Gastrointestinal tract inflammation | Dial |
||
Improves intestinal barrier function. | Drug-induced Liver injury | Chen |
||
Polyenylphosphatidylcholine | Protective effects against lipid peroxidation, oxidative stress and hepatic fibrosis | Fatty liver, metabolic comorbidities | Maev |
|
PI | Phosphatidylinositol (3, 4, 5) – trisphosphate (PI(3,4,5)P3) |
Signaling molecule processed by phosphatidylinositol 3-kinase | Insulin resistance | Kachko |
PS | PS | Suppress the TNF-α production of peritoneal macrophage | Inflammatory disease | Klein |
Interfere with the pro-inflammatory cytokine formation of phagocyte | Inflammatory disease | Szondy |
||
Lecithin-transphosphatidylated PS | Restored age-associated decreases of choline transporter | Memory impairment | Lee |
|
Plasmalogen | Ethanolamine plasmalogen | Correlation of declined circulating plasmalogen and cognitive function | Alzheimer’s disease | Wood |
Enhanced inhibition activity of phosphatidylethanolamine on γ-secretase | Alzheimer’s disease | Onodera |
||
Improvement of cognitive functions | Alzheimer’s disease | Fujino |
||
Improved memory impairment in amyloid β-infused rats | Alzheimer’s disease | Yamashita |